Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade

Guido Kroemer, Oliver Kepp

    Research output: Contribution to journalEditorial

    14 Citations (Scopus)

    Abstract

    Sequential combination of immunogenic cell death (ICD)-induced interventions with subsequent immunotherapy has shown efficacy in preclinical models and clinical evaluation. Recently, a clinical trial enrolling small cell lung cancer patients treated with amrubicin together with PD-1 blockade confirmed the notion that ICD sensitizes tumors to immune checkpoint inhibitors.

    Original languageEnglish
    Article number1996686
    JournalOncoImmunology
    Volume10
    Issue number1
    DOIs
    Publication statusPublished - 1 Jan 2021

    Keywords

    • Immunotherapy
    • anthracycline
    • lung cancer

    Cite this